SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Jürg Bernhard, Klazien Matter‐Walstra et al.|BMC Cancer|2016Cited by 46
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Christoph Rochlitz, Khalil Zaman, Thomas Ruhstaller et al.|Annals of Oncology|2010Cited by 26